Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Patrick Sulzgruber; Sven Wassmann; Anne Grete Semb; Wolfram Doehner; Petr Widimsky; Thomas Gremmel; Juan Carlos Kaski; Gianluigi Savarese; Giuseppe M C Rosano; Claudio Borghi; Keld Kjeldsen; Christian Torp-Pedersen; Thomas Andersen Schmidt; Basil S Lewis; Heinz Drexel; Juan Tamargo; Dan Atar; Stefan Agewall; Alexander Niessner

doi:10.1093/ehjcvp/pvz016

Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, Wolfram Doehner, Petr Widimsky, Thomas Gremmel, Juan Carlos Kaski, Gianluigi Savarese, Giuseppe M C Rosano, Claudio Borghi, Keld Kjeldsen, Christian Torp-Pedersen, Thomas Andersen Schmidt, Basil S Lewis, Heinz Drexel, Juan Tamargo, Dan Atar, Stefan Agewall, Alexander Niessner

Research output: Contribution to journal › Review article › peer-review

47 Citations (Scopus)

109 Downloads (Pure)

Abstract

Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

Original language	English
Article number	pvz016
Journal	European Heart Journal - Cardiovascular Pharmacotherapy
Volume	5
Issue number	3
Pages (from-to)	171–180
Number of pages	10
ISSN	2055-6837
DOIs	https://doi.org/10.1093/ehjcvp/pvz016
Publication status	Published - Jul 2019

Bibliographical note

Keywords

Atrial fibrillation
CHA2DS2-VASc score
Intermediate risk
Anticoagulation
CHA DS -VASc score
Anticoagulation

Access to Document

10.1093/ehjcvp/pvz016

Green Open Access manuscriptAccepted author manuscript, 1.71 MB

AUB Link

Search for the material in Aalborg University Library's search engine

Fingerprint

Dive into the research topics of 'Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke'. Together they form a unique fingerprint.

Cite this

Sulzgruber, P., Wassmann, S., Semb, A. G., Doehner, W., Widimsky, P., Gremmel, T., Kaski, J. C., Savarese, G., Rosano, G. M. C., Borghi, C., Kjeldsen, K., Torp-Pedersen, C., Schmidt, T. A., Lewis, B. S., Drexel, H., Tamargo, J., Atar, D., Agewall, S., & Niessner, A. (2019). Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. European Heart Journal - Cardiovascular Pharmacotherapy, 5(3), 171–180. Article pvz016. https://doi.org/10.1093/ehjcvp/pvz016

Sulzgruber, Patrick ; Wassmann, Sven ; Semb, Anne Grete et al. / Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 : a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. In: European Heart Journal - Cardiovascular Pharmacotherapy. 2019 ; Vol. 5, No. 3. pp. 171–180.

@article{86185084143c4942933721cc38938134,

title = "Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke",

abstract = "Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.",

keywords = "Atrial fibrillation, CHA2DS2-VASc score, Intermediate risk, Anticoagulation, CHA DS -VASc score, Anticoagulation",

author = "Patrick Sulzgruber and Sven Wassmann and Semb, {Anne Grete} and Wolfram Doehner and Petr Widimsky and Thomas Gremmel and Kaski, {Juan Carlos} and Gianluigi Savarese and Rosano, {Giuseppe M C} and Claudio Borghi and Keld Kjeldsen and Christian Torp-Pedersen and Schmidt, {Thomas Andersen} and Lewis, {Basil S} and Heinz Drexel and Juan Tamargo and Dan Atar and Stefan Agewall and Alexander Niessner",

year = "2019",

month = jul,

doi = "10.1093/ehjcvp/pvz016",

language = "English",

volume = "5",

pages = "171–180",

journal = "European Heart Journal - Cardiovascular Pharmacotherapy",

issn = "2055-6837",

publisher = "Oxford University Press",

number = "3",

}

Sulzgruber, P, Wassmann, S, Semb, AG, Doehner, W, Widimsky, P, Gremmel, T, Kaski, JC, Savarese, G, Rosano, GMC, Borghi, C, Kjeldsen, K, Torp-Pedersen, C, Schmidt, TA, Lewis, BS, Drexel, H, Tamargo, J, Atar, D, Agewall, S & Niessner, A 2019, 'Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke', European Heart Journal - Cardiovascular Pharmacotherapy, vol. 5, no. 3, pvz016, pp. 171–180. https://doi.org/10.1093/ehjcvp/pvz016

Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. / Sulzgruber, Patrick; Wassmann, Sven; Semb, Anne Grete et al.
In: European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 5, No. 3, pvz016, 07.2019, p. 171–180.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1

T2 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

AU - Sulzgruber, Patrick

AU - Wassmann, Sven

AU - Semb, Anne Grete

AU - Doehner, Wolfram

AU - Widimsky, Petr

AU - Gremmel, Thomas

AU - Kaski, Juan Carlos

AU - Savarese, Gianluigi

AU - Rosano, Giuseppe M C

AU - Borghi, Claudio

AU - Kjeldsen, Keld

AU - Torp-Pedersen, Christian

AU - Schmidt, Thomas Andersen

AU - Lewis, Basil S

AU - Drexel, Heinz

AU - Tamargo, Juan

AU - Atar, Dan

AU - Agewall, Stefan

AU - Niessner, Alexander

PY - 2019/7

Y1 - 2019/7

N2 - Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

AB - Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

KW - Atrial fibrillation

KW - CHA2DS2-VASc score

KW - Intermediate risk

KW - Anticoagulation

KW - CHA DS -VASc score

KW - Anticoagulation

UR - http://www.scopus.com/inward/record.url?scp=85068427343&partnerID=8YFLogxK

U2 - 10.1093/ehjcvp/pvz016

DO - 10.1093/ehjcvp/pvz016

M3 - Review article

C2 - 31119266

SN - 2055-6837

VL - 5

SP - 171

EP - 180

JO - European Heart Journal - Cardiovascular Pharmacotherapy

JF - European Heart Journal - Cardiovascular Pharmacotherapy

IS - 3

M1 - pvz016

ER -

Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T et al. Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. European Heart Journal - Cardiovascular Pharmacotherapy. 2019 Jul;5(3):171–180. pvz016. doi: 10.1093/ehjcvp/pvz016

Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Abstract

Bibliographical note

Keywords

Access to Document

AUB Link

Other files and links

Fingerprint

Cite this